Correlations between clinical parameters and interleukin-6 and interleukin-10 levels in saliva from totally edentulous patients with peri-implant disease

International Journal of Oral and Maxillofacial Implants

Volumn 21, Issue 4, 2006, Pages 543-550

  Liskmann, Stanislav ^a   Vihalemm, Tiiu ^a   Salum, Olev ^a   Zilmer, Kersti ^a   Fischer, Krista ^a   Zilmer, Mihkel ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Dental implants; Interleukin 10; Interleukin 6; Peri implant disease; Peri implantitis; Saliva

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6;

ADULT; ARTICLE; CHEMISTRY; DENTURE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MOUTH DISEASE; NONPARAMETRIC TEST; PERIODONTAL DISEASE; PERIODONTICS; SALIVA; TOOTH IMPLANTATION; TOOTH PROSTHESIS;

ADULT; DENTAL IMPLANTS; DENTAL PROSTHESIS, IMPLANT-SUPPORTED; DENTURE, OVERLAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MOUTH, EDENTULOUS; PERIODONTAL DISEASES; PERIODONTAL INDEX; SALIVA; STATISTICS, NONPARAMETRIC;

EID: 33748513266     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. James RA, Lozada JL. The peri-implant tissues: Seal and support. In: Kawahara J (ed). Oral Implantology and Biomaterials. Amsterdam: Elsevier Science Publishers, 1989:209-218.
2. Berglundh T, Lindhe J, Ericsson I, Marinello CP, Liljenberg B, Thomsen P. The soft tissue barrier at implants and teeth. Clin Oral Implants Res 1991;2:81-90.
3. Listgarten MA, Lang NP, Schroeder HE, Schroeder A. Periodontal tissues and their counterparts around endosseous implants. Clin Oral Implants Res 1991;2(3):1-19.
4. Albrektsson T, Isidor F. Consensus report of session IV (Implant Dentistry). In: Lang NP, Karring T (eds). Proceedings of the 1st European Workshop on Periodontology. London: Quintessence, 1994:365-369.
5. Berglundh T, Lindhe J, Marinello C, Ericsson I, Liljenberg B. Soft tissue reaction to de novo plaque formation on implants and teeth. An experimental study in the dog. Clin Oral Implants Res 1992;3(1):1-8.
6. Leonhardt Å, Berglundh T, Ericsson I, Dahlen G. Putative periodontal pathogens on titanium and teeth in experimental gingivitis and periodontitis in beagle dogs. Clin Oral Implants Res 1992;3(1):112-119.
7. Leonhardt Å, Renvert S, Dahlen G. Microbial findings at failing implants. Clin Oral Implants Res 1999;10:339-345.
8. Pontoriero R, Tonetti MP, Carnevale G, Mombelli A, Nyman S, Lang NP. Experimentally induced peri-implant mucositis. A clinical study in humans. Clin Oral Implants Res 1994;5:254-259.
9. Jandinski JJ, Stashenko P, Feder LS, et al. Localization of interleukin-1α in human periodontal tissue. J Periodontol 1991;62:36-43.
10. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991;62:504-509.
11. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998;9:248-266.
12. Stashenko P, Fujiyoshi P, Obernesser MS, Prostak L, Haffajee AD, Socransky SS. Levels of interleukin-1α in tissue from sites of active periodontal disease. J Clin Periodontol 1991;18:548-554.
13. Figueredo CMS, Ribeiro MSM, Fischer RG, Gustafsson A. Increased interleukin-1β concentration in gingival crevicular fluid as a characteristic of periodontitis. J Periodontol 1999;70:1457-1463.
14. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-588.
15. Dewhirst FE, Stashenko P, Mole JE, Tsurumachi T. Purification and partial sequence of human osteoclast activating factor: Identity with interleukin 1β. J Immunol 1985;135:2562-2568.
16. Billingham MEJ. Cytokines as inflammatory mediators. Br Med Bull 1987;43:350-370.
17. Lorenzo JA, Sousa SL, Alender C, Raisz G, Dinarello CA. Comparison of bone resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum IL-1. Endocrinology 1987;121:1164-1170.
18. 2 production by osteoblastic cells: Synergy with parathyroid hormone. Calcified Tissue Int 1988;42:358-362.
19. Van-Snick J. Interleukin-6: An overview. Ann Rev Immunol 1990;8:253-278.
20. Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res 1991;26:230-242.
21. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3297-3303.
22. Kono Y, Beagley KW, Fujihashi K, et al. Cytokine regulation of localized inflammation: Induction of activated B cells and IL-6 mediated polyclonal 1gG and 1gA synthesis in inflamed human gingiva. J Immunol 1991;146:1812-1821.
23. Bartold PM, Haynes DR. Interleukin-6 production by human gingival fibroblasts. J Periodontal Res 1991;26:339-345.
24. Matsuki Y, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 1992;76:42-47.
25. Geivelis M, Turner DW, Pederson ED, Lamberts BL. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 1993;64:980-983.
26. Roussel F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated humab B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
27. Itoh K, Inoue T, Ito K, Hirohata S. The interplay of interleukin-10 (IL-10) and interleukin-2 (IL-2) in humoral immune responses: IL-10 synergizes with IL-2 to enhance responses of human B lymphocytes in a mechanism which is different from upregulation of CD25 expression. Cell Immunol 1994;157:478-488.
28. Berg DJ, Kuhn R, Rajewsky K, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Schwarzmann reaction but not endotoxine tolerance. J Clin Invest 1995;96:2339-2347.
29. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) Th1-like responses. J Clin Invest 1996;98:1010-1020.
30. Al-Rasheed A, Scheerens H, Rennick DM, Fletcher HM, Tatakis DN. Accelerated alveolar bone loss in mice lacking interleukin-10. J Dent Res 2003;82:632-635.
31. Cuzzocrea S, Mazzon E, Dugo L, et al. Absence of endogenous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Netw 2001;12:568-580.
32. Puliti M, Von Hunolstein C, Verwaerde C, Bistoni F, Orefici G, Tissi L. Regulatory role of interleukin-10 in experimental group B streptococcal arthritis. Infect Immunol 2002;70:2862-2868.
33. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
34. Kucharzik T, Lugcring N, Weigelt H, Adolf M, Domschke W, Stoll R. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. Clin Exp Immunol 1996;104:483-490.
35. Sagawa K, Mochizuki M, Sugita S, Nagai K, Sudo T, Itoh K. Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction. Cytokine 1996;8:501-506.
36. Hart PH, Jones CA, Finlay-Jones JJ. Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10. J Leukoc Biol 1995;57:909-918.
37. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappaB (NF-kappaB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-9563.
38. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989;7:145-173.
39. Fiorentino DF, Zlotik A, Vicira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-3451.
40. Sasaki H, Hou L, Belani A, et al. IL-10, but not IL-4, suppresses infection-stimulated bone resorption in vivo. J Immunol 2000;165:3626-3630.
41. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
42. Leigh JE, Steele C, Wormley F, Fidel PL Jr. Salivary cytokine profiles in the immunocompetent individual with Candida-associated denture stomatitis. Oral Microbiol Immunol 2002;17:311-314.
43. Slavisnsky J, Myers T, Swoboda RK, Leigh JE, Hager S, Fidel PL Jr. Th1/Th2 cytokine profiles in saliva of HIV-positive smokers with oropharyngeal candidiasis. Oral Microbiol Immunol 2001;17:38-43.
44. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005;114:278-283.
45. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533-551.
46. Lang NP, Wetzel AC, Stich H, Caffesse RG. Histologic probe penetration in healthy and inflamed peri-implant tissues. Clin Oral Implants Res 1994;5:191-201.
47. Karayannis A, Lang NP, Joss A, Nyman S. Bleeding on probing as it relates to probing pressure and gingival health in patients with a reduced but healthy periodontium. J Clin Periodontol 1992;19:471-475.
48. Pontoriero R, Tonelli MP, Carnevale G, Mombelli A, Nyman SR, Lang NP. Experimentally induced peri-implant mucositis: A clinical study in humans. Clin Oral Implants Res 1994;5:254-259.
49. Mombelli A, Lang NP. The diagnosis and treatment of peri-implantitis. Periodontol 2000 1998;17:63-70.
50. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage into the oral mucosa and its effects on the measurements of cortisol, dehydroepiandrosterone, and testosterone in saliva. Horm Behav 2004;46:39-46.
51. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
52. Leigh JE, Barousse M, Swoboda RK. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 2001;183:277-285.
53. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989;44:153-205.
54. Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren's syndrome. J Rheumatol 1997;24:1089-1091.
55. Sjögren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: Studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun 2006;20:270-278.
56. Boras VV, Cikes N, Lukac J, Cekic-Arambasin A, Virag M, Bosnjak A. The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjögren's syndrome. Coll Antropol 2004;28(suppl 2):305-309.
57. Minetto M, Rainoldi A, Gazzoni M, et al. Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. Eur J Appl Physiol 2005;93:679-686.
58. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-223.
59. Kamma JJ, Giannopoulou C, Vasdekis VGS, Mombelli A. Cytokine profile in gingival crevicular fluid of aggressive periodontitis: Influence of smoking and stress. J Clin Periodontol 2004;31:894-902.
60. Rhodus N, Dahmer L, Lindemann K, Rudney J, Mathur A, Bereuter J. s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hyrochloride administration: A pilot study. Clin Oral Investig 1998;2:191-196.
61. Streckfus C, Bigler L, Navazesh M, Al-Hashimi I. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: A preliminary study. Clin Oral Investig 2001;5:133-135.
62. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999;58:253-256.
63. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Invest 1976;33:235-249.
64. Onoe Y, Miyaura C, Kaminakayashiki T, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996;156:758-764.
65. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. Inhibition of tumor necrosis factor-α-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways. Arthritis Rheum 1999;42:710-718.
66. Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol 1996;157:936-940.
67. Xu LX, Kukita T, Otsuka T, Niho Y, Iijima T. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol 1995;165:624-629.
68. Yamamoto M, Fujihashi K, Hiroi T, McGee JR, Van Dyke TE, Kiyono H. Molecular and cellular mechanism for periodontal diseases: Role of Th1 and Th2 type cytokines in induction of mucosal inflammatory. J Periodontal Res 1997;32:115-119.
69. Gemmel E, Kjeldsen M, Yamazaki K, Nakayima T, Aldred MJ, Seymour GJ. Cytokine profiles of Porphyromanas gingivalis-reactive T lymphocyte lines and clones derived from P gingivalis-infected subjects. Oral Dis 1995;1:139-146.
70. Gemmell E, Marshall R, Seymour G. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol 2000 1997;14:112-143.
71. Reinhardt RA, Masada MP, Kaldhal WB, et al. Gingival fluid IL-1 and IL-6 levels in refractory periodontitis. J Clin Periodontol 1993;20:225-231.
72. Rossomando E, Kennedy JE, Hadjimichael J. Tumor necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol 1990;35:431-434.
73. Yamazaki K, Nakajima TEG, Polak B, Seymour E, Hara K. IL-4- and IL-6-producing cells in human periodontal disease tissue. J Oral Pathol Med 1994;23:347-353.
74. Jinquian T, Larsen CG, Gesser B, Matsushima K, Thestrup-Pedersen K. Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 1992;151:4545-4551.
75. Oringer RJ. Research, Science and Therapy Committee of the American Academy of Periodontology. Modulation of the host response in periodontal therapy. J Periodontol 2002;73:460-470 [erratum 2002;73:684].
76. Liskmann S, Zilmer M, Vihalemm T, Salum O, Fischer K. Correlation of peri-implant health and myeloperoxidase levels: A cross-sectional clinical study. Clin Oral Implants Res 2004;15:546-552.
77. Schierano G, Bellone G, Cassarino E, Pagano M, Preiti G, Emanuelli G. Tranforming growth factor-β and interleukin-10 in oral implant sites in humans. J Dent Res 2003;82(6):428-432.